Rohit Malik
Therapies targeting the androgen receptor (AR) are the primary treatment approach for metastatic prostate cancer. Patients eventually progress to an aggressive drug-resistant disease state termed castrate-resistant prostate cancer (CRPC). Dr....Read More
John Chadwick Brenner
More than 50% of prostate cancers have a common underlying rearrangement of genes that leads to the abnormal fusion of two genes, TMPRSS2 and ERG and the overexpression of ERG....Read More
Ulrich Rodeck, MD, PhD
Improving the Therapeutic Window of Radiation Therapy for Prostate Cancer Radiation therapy of locally advanced prostate cancer is associated with severe toxicity limits. Dr. Rodeck will test the hypothesis that...Read More
Everardo Macias
Development and progression of prostate cancer is associated with obesity, suggesting that therapeutic targeting of metabolic factors may represent a novel treatment strategy. However, caloric restriction to target the metabolic...Read More
Rajan Kulkarni
Prostate cancer diagnosis and precision medicine decisions are currently informed by analysis of tissues obtained by invasive biopsy procedures. Circulating tumor cells (CTCs) are cells that have been shed from...Read More
Haydn Kissick
T cells are immune cells with a specialized and powerful ability to recognize dangerous cells and kill them. This occurs by T cell recognition of antigens, i.e. small segments of...Read More
Joshi Alumkal, MD
Dr. Joshi Alumkal is a Professor of Internal Medicine at the University of Michigan. Raised in Texas, Dr. Alumkal graduated summa cum laude from the University of Texas with a...Read More
William Polkinghorn, MD
Defining the role of AR Signaling in Promoting Prostate Cancer Radioresistance Dr. Polkinghorn postulates that androgen receptor signaling directly promotes prostate cancer resistance to radiation therapy (radioresistance). This work will...Read More
Charalambos Kaittanis
The poor solubility and bioavailability of many prostate cancer medicines forces physicians to prescribe higher doses to patients to obtain a clinical response. Targeted delivery of drugs to tumors could...Read More
Neema Jamshidi
The ability of physicians to more accurately differentiate indolent from aggressive prostate tumors is critical to eliminate the current problem of overdiagnosis and overtreatment of many patients while missing aggressive...Read More